Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Neutral Rating, Lowers PO on Boston Scientific

Share:
Related BSX
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
Opinion: Here Are 10 Trends (And 11 Investments) To Watch In 2015

In a report published Friday, Bank of America Merrill Lynch reiterated its Neutral rating on Boston Scientific (NYSE: BSX), but lowered its price objective from $8.50 to $6.30.

BofA Merrill Lynch noted, “In order to be more bullish on BSX, we need more conviction that ASP declines in BSX's core drug-eluting stent market will moderate and the Promus Element stent can be successful in the U.S. in order to allow for operating leverage, and we need more conviction that BSX can grow. If we became more convinced that operating leverage will materialize, it would make it much easier to call BSX cheap and to argue that a positive risk reward exists while we wait for management's plan to play out.”

Boston Scientific closed on Thursday at $5.66.

Latest Ratings for BSX

DateFirmActionFromTo
Jan 2015Leerink SwannUpgradesMarket PerformOutperform
Oct 2014Goldman SachsUpgradesSellNeutral
Oct 2014BenchmarkUpgradesHoldBuy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters